Form 4: Bristol-Myers Squibb Director Phyllis Yale Reports Acquisition of Deferred Share Units

Director Phyllis Yale acquired 618.812 deferred share units of Bristol-Myers Squibb on December 31, 2024, convertible to common stock upon settlement.

Summary

• Phyllis Yale, a director at Bristol-Myers Squibb, reported the acquisition of 618.812 deferred share units on December 31, 2024.
• These deferred share units will convert into shares of common stock upon settlement, which occurs when Ms. Yale ceases to be a director or at a previously specified future date.
• The transaction was priced at $56.56 per unit, and the total number of units beneficially owned following the transaction is 30,796.367.
• The reported holdings include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: The document is a routine SEC filing related to director compensation, which is neither positive nor negative. It is a neutral event that is expected for a public company.

Industry Context

This is a routine filing related to director compensation and is typical for publicly traded companies. It reflects the standard practice of granting deferred share units to board members.

Comparison to Industry Standards

• The use of deferred share units as part of director compensation is a common practice among large publicly traded companies, including pharmaceutical companies like Pfizer and Merck.
• These units typically vest over time or upon certain events, such as retirement, aligning director interests with long-term shareholder value.
• The specific terms of the deferred share units, such as the settlement date and conversion ratio, are consistent with industry norms for director compensation packages.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with the long-term performance of the company.
• The acquisition of deferred share units is part of the director's compensation package and does not have a direct impact on employees, customers, or suppliers.

Key Dates

Keywords

Deferred Share Units, Director, Form 4, Bristol-Myers Squibb, Phyllis Yale, Insider Trading, SEC Filing